Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2995

1.

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F.

Vaccine. 1999 Apr 9;17(15-16):1869-82.

PMID:
10217584
2.

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett AD, Nichols R, Weltzin R, Arroyo J, Guirakhoo F.

J Virol. 2000 Feb;74(4):1742-51.

4.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

PMID:
14551893
5.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

7.

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F.

Vaccine. 2002 Jan 15;20(7-8):1004-18.

PMID:
11803060
9.

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

Chambers TJ, Nestorowicz A, Mason PW, Rice CM.

J Virol. 1999 Apr;73(4):3095-101.

10.

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP.

Virology. 2002 Jun 20;298(1):146-59.

12.

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.

Yu Y.

Vaccine. 2010 May 7;28(21):3635-41. doi: 10.1016/j.vaccine.2010.02.105. Epub 2010 Mar 11. Review.

PMID:
20226891
13.

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP.

Hum Vaccin. 2006 Mar-Apr;2(2):60-7. Epub 2006 Mar 15.

PMID:
17012873
14.

An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys.

Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):329-37.

PMID:
10466957
15.

Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.

Monath TP, Myers GA, Beck RA, Knauber M, Scappaticci K, Pullano T, Archambault WT, Catalan J, Miller C, Zhang ZX, Shin S, Pugachev K, Draper K, Levenbook IS, Guirakhoo F.

Biologicals. 2005 Sep;33(3):131-44.

PMID:
15975826
16.

Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).

Reid M, Mackenzie D, Baron A, Lehmann N, Lowry K, Aaskov J, Guirakhoo F, Monath TP.

Am J Trop Med Hyg. 2006 Oct;75(4):659-63.

PMID:
17038690
17.

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ.

J Virol. 2001 Jan;75(2):934-42.

18.

IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.

Appaiahgari MB, Vrati S.

Expert Rev Vaccines. 2010 Dec;9(12):1371-84. doi: 10.1586/erv.10.139. Review.

PMID:
21105774
19.

Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.

Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):343-9.

PMID:
10466959
20.

Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys.

Trindade GF, Marchevsky RS, Fillipis AM, Nogueira RM, Bonaldo MC, Acero PC, Caride E, Freire MS, Galler R.

An Acad Bras Cienc. 2008 Jun;80(2):311-21.

Supplemental Content

Support Center